XML 11 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 105.2 $ 258.4
Marketable investment securities 99.9 81.4
Trade accounts receivable 109.8 91.3
Inventory 15.4 15.3
Prepaid taxes 19.2 18.4
Prepaid expenses and other current assets 17.6 20.0
Total current assets 367.1 484.8
Operating lease right-of-use assets 82.9 81.8
Long-term marketable investment securities 78.5 59.0
Property, plant, and equipment, net 52.8 43.5
Intangibles, net 382.3 404.1
Goodwill 237.8 239.2
Other assets 8.8 8.3
Total assets 1,210.2 1,320.7
Current liabilities:    
Accounts payable 21.7 29.6
Accrued liabilities 84.4 156.5
Current maturities of operating lease liabilities 13.3 13.0
Deferred revenues 0.3 5.2
Total current liabilities 119.7 204.3
Unrecognized tax benefits 27.7 27.9
Long-term deferred taxes 23.3 35.8
Noncurrent operating lease liabilities 87.4 79.3
Other long-term liabilities 4.7 5.6
Total liabilities 262.8 352.9
Commitments and contingencies
Stockholders’ equity:    
Common stock, 80.6 million and 80.0 million shares outstanding at June 30, 2022 and December 31, 2021, respectively 0.8 0.8
Additional paid-in capital 1,244.3 1,226.3
Accumulated other comprehensive loss (8.9) (5.1)
Accumulated deficit (288.8) (254.2)
Total Myriad Genetics, Inc. stockholders’ equity 947.4 967.8
Non-controlling interest 0.0 0.0
Total stockholders' equity 947.4 967.8
Total liabilities and stockholders’ equity $ 1,210.2 $ 1,320.7